Learning objectives
Definition of theranostics.
Intoduction to neuroendocrine tumors.
Applications of theranostics in neuroendocrine tumors.
Background
In nuclear medicine,
theranostics refer to the use of molecules marked with radionuclides for diagnostic and / or therapeutic purposes.3,4
Neuroendocrine tumors (NETs) are a heterogeneous group of neoplasms that originate from the neuroendocrine system,
the gastrointestinal and bronchial tracts,
the prevalence of these tumors is low,
survival rates of more than 5 years have now been reported.1,2
When disease is localized,
the treatment of first choice is surgery; however,
a high percentage of patients present metastatic disease at the time of diagnosis.
When surgery...
Findings and procedure details
We present a case of a 73 year old male patient diagnosed with neuroendocrine carcinoma of the small intestine,
metastatic to liver.
He debuted with abdominal pain in 2006,
performing diagnostic exploratory laparotomy,
withintestinal resection due to tumor in proximal jejunum.
Histopathological report was well differentiated carcinoid tumor (Ki67 <2%).
For the initial staging,
scintigraphy with Octreotide was performed where liver lesions were identified and treatment with Sandostatin was initiated.
It remains in surveillance until 2015 where progression of the disease is identified in PET-CT...
Conclusion
Applications to therapeutic radiopharmaceuticals has increased worldwide due to the benefits they have shown in the diagnosis and treatment of NETs in advanced stages; these allow a better evaluation of the extent of the disease through the PET/CT 68GA-DOTANOC studies,
in addition to that the therapy with 177Lu-DOTANOC increases the survival and the period free of progression.
References
N Engl J Med 2017;376:125-35
J Thorac Dis.
2017 Nov;9(Suppl 15):S1511-S1523
The lancet Oncology January 2008,
Vol 9 no 1,
p61-72
Eur J of Nucl Med Mol Imaging,
2015 Aug,
vol.
42 no 9,
p1341-1352
J Nucl Med January 1,
2018 vol.
59 no.
1 66-74
Eur J Nucl Med Mol Imaging.
2013 May;40(5):800-16.
Future Oncol.
2014 Nov;10(14):2259-7
Scand J Gastroenterol.
2015 Jun;50(6):740-7
J Nucl Med.
2010 May;51(5):704-12.